Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CARvac in Relapsed/Refractory B Cell Malignancies
NCT04156243Phase 1Unknown
- Sponsor
- iCell Gene Therapeutics
- Start
- Feb 2018
- Primary completion
- Feb 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CARvac in B cell lymphoma and B-cell leukemia (BCL), sponsored by iCell Gene Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days, Type of Dose-Limiting Toxicity at 28 days and 1 more. Status: unknown.
02
Drugs
CD19 CARvac
03
Conditions
B cell lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT04156243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156243.